VYNE Therapeutics (NASDAQ:VYNE) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note released on Monday morning,Benzinga reports. They currently have a $5.75 target price on the stock.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Stock Down 8.4 %

VYNE stock opened at $3.92 on Monday. The business has a 50 day moving average of $2.95 and a 200 day moving average of $2.31. The firm has a market cap of $57.82 million, a PE ratio of -4.56 and a beta of 1.30. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.30.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is currently owned by institutional investors and hedge funds.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.